[Successful Re-Administration of Nivolumab in Patient with Metastatic Renal Cell Carcinoma : A Case Report]

Hinyokika Kiyo. 2021 Dec;67(12):525-528. doi: 10.14989/ActaUrolJap_67_12_525.
[Article in Japanese]

Abstract

A 46-year-old woman was referred to our hospital with a left-sided renal tumor pointed out by ultrasonography at the time of a medical checkup.Computed tomography revealed a mass measuring 88×77×68 mm on the upper pole of the left kidney. She was diagnosed with cT2aN0M0 clear cell renal cell carcinoma. Laparoscopic left nephrectomy was performed uneventfully. Histopathological diagnosis was clear cell renal cell carcinoma, G2, v1, pT2. Four months after surgery, lung metastases appeared, and systemic therapy was given sequentially as follows ; sunitinib for 2 months, nivolumab for 8 months, axitinib for 17 months, and pazopanib for 2 months.However, metastases progressed, and a re-administration of nivolumab was planned. The nivolumab re-treatment resulted in a marked reduction in multiple lung metastases despite the previous failure by nivolumab treatment. There are few reports on the therapeutic effect of re-administration of nivolumab. We report a case of successful treatment by re-administration of nivolumab.

Publication types

  • Case Reports

MeSH terms

  • Axitinib
  • Carcinoma, Renal Cell* / diagnostic imaging
  • Carcinoma, Renal Cell* / drug therapy
  • Carcinoma, Renal Cell* / surgery
  • Female
  • Humans
  • Kidney Neoplasms* / diagnostic imaging
  • Kidney Neoplasms* / drug therapy
  • Kidney Neoplasms* / surgery
  • Middle Aged
  • Nivolumab / therapeutic use
  • Sunitinib

Substances

  • Nivolumab
  • Axitinib
  • Sunitinib